<?xml version="1.0" encoding="UTF-8" ?><dbgapss xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbgapssws.1.0.xsd"><Study uid="41125" whole_study_id="41125" phs="002377" v="1" p="1" createDate="2021-03-09T14:44:30-05:00" completedByGPADate="2021-03-10T07:56:40-05:00" modDate="2021-09-03T22:28:53-05:00" maxParentChildStudyModDate="2021-09-03T22:28:53-05:00" handle="Ipilimumab_Nivolumab_HCT" num_participants="71"><StudyInfo accession="phs002377.v1.p1" parentAccession="phs002377.v1.p1"><BioProject id="PRJNA713432" entrez_id="713432" type="bp_admin_access"/><BioProject id="PRJNA713433" entrez_id="713433" type="bp_data_submission"/><StudyNameEntrez>A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation</StudyNameEntrez><StudyTypes2 calculated="Yes"><StudyType21 name="phenotype_data" chosen="Yes"/><StudyType21 name="analysis" chosen="No"/><StudyType21 name="individual_sequencing" chosen="Yes"><StudyType22 name="ncbi_for_sequence"/><StudyType22 name="rnaseq_whole_targ_transcriptome"/></StudyType21><StudyType21 name="supporting_documents" chosen="No"/><StudyType21 name="images" chosen="No"/><StudyType21 name="molecular" chosen="No"/><StudyType21 name="subject_samples" chosen="Yes"><StudyType22 name="tumor_normal"/><StudyType22 name="rna"/></StudyType21><StudyType21 name="links_to_ncbi_dbs" chosen="No"/><StudyType21 name="other_general" chosen="No"/></StudyTypes2><StudyTypes><StudyType>phenotype_data</StudyType><StudyType>individual_sequencing</StudyType><StudyType>tumor_normal</StudyType><StudyType>rna</StudyType><StudyType>whole_transcriptome</StudyType><StudyType>sra</StudyType></StudyTypes><SraStorages><SraStorage location="Amazon Cloud"><Person email="feolo@ncbi.nlm.nih.gov"><Role>Cloud Service Administrator</Role></Person><Person email="feolo@ncbi.nlm.nih.gov"><Role>Data steward</Role></Person></SraStorage><SraStorage location="Google Cloud"><Person email="feolo@ncbi.nlm.nih.gov"><Role>Cloud Service Administrator</Role></Person><Person email="feolo@ncbi.nlm.nih.gov"><Role>Data steward</Role></Person></SraStorage></SraStorages></StudyInfo><Authority><ICs><IC id="4" name="NCI" is_funding_ic="true" is_admin_ic="true" primary="true"/></ICs><Persons><Person nedid="CWU001" aid="2" auth="eRA" login="CWU001" fname="Catherine" mname="JU-YING" lname="Wu" email="cwu@partners.org"><Role allow_direct_access="true">PI</Role><Organization>DANA-FARBER CANCER INST</Organization></Person><Person nedid="0011061339" aid="1" auth="cit" login="thurinm" fname="Magdalena" mname="" lname="Thurin" email="mt244h@nih.gov"><Role>PO</Role><Organization>NIH</Organization></Person><Person aid="8" auth="virtual" fname="Sam" lname="Pollock" email="spollock@broadinstitute.org"><Role>PI_ASSIST</Role><Organization/></Person><Person nedid="0013269007" aid="1" auth="cit" login="kianga" fname="Anne" mname="" lname="Sturcke" email="kianga@ncbi.nlm.nih.gov"><Role>PHENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011559580" aid="1" auth="cit" login="stefanov" fname="Stefan" mname="Alexandrov" lname="Stefanov" email="stefanov@mail.nih.gov"><Role>GENO_CURATOR</Role><Organization>NIH</Organization></Person><Person nedid="0011059039" aid="1" auth="cit" login="withersk" fname="Kim" mname="Juanita" lname="Witherspoon" email="kw265c@nih.gov"><Role>GPA</Role><Organization>NIH</Organization></Person></Persons></Authority><Policy display-research-statement="true" display-public-summary="true" years-until-renewal="1" weeks-to-cancel-request="8" pub-embargo="none"><acknowledgement_statement>This work was supported by grants from the National Cancer Institute of the National Institutes of Health (P01CA229092 to C.J.W.; 5R01CA183559, 5R01CA183560 and 5UM1CA186709 (PI: Geoffrey Shapiro, M.D., Ph.D.)), National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, LLS Therapy Accelerator Program. L.P. is supported by a research fellowship from the German Research Foundation (DFG, PE 3127/1-1). S.L. is supported by the NCI Research Specialist Award (R50CA251956-01). P.B. is supported by NCI grant K08CA248458 and the Amy Strelzer Manasevit Research Program which is funded through Be The Match Foundation. P.B. is a Scholar of the American Society of Hematology. M.S.D. and P.A. are both Scholars in Clinical Research from the Leukemia &amp; Lymphoma Society. S.G. is supported by grants U01DK124165 and P01CA190174. N.C. is supported by an AACR-Incyte Immuno-oncology Research Fellowship (20-40-46-CEIR). The Human Immune Monitoring Center at ISMMS received support from the Cancer Center Support Grant CA196521.    Scientific and financial support for the CIMAC-CIDC Network is provided through the National Cancer Institute (NCI) Cooperative Agreements U24CA224319 (to the Icahn School of Medicine at Mount Sinai CIMAC), U24CA224331 (to the Dana-Farber Cancer Institute CIMAC), and U24CA224316 (to the CIDC at Dana-Farber Cancer Institute). Additional support is made possible through the NCI CTIMS Contract HHSN261201600002C. Scientific and financial support for the PACT project are made possible through funding support provided to the FNIH by: AbbVie Inc., Amgen Inc., Boehringer-Ingelheim Pharma GmbH &amp; Co. KG., Bristol-Myers Squibb, Celgene Corporation, Genentech Inc, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical Companies of Johnson &amp; Johnson, Novartis Institutes for Biomedical Research, Pfizer Inc., and Sanofi. The CIMAC-CIDC website is found at https://cimac-network.org/.   </acknowledgement_statement><ic_specific_access_term/><DUC><File uri="dbgapssws.cgi?blob_id=41130&amp;file=get&amp;page=file" filename="dbGaP 9204 Wu NCI CTEP DUCA 3 9 21.pdf" md5="5c0a934c14b8c952212eb379b910fb85" size="435960" modDate="2021-03-09T15:01:12-05:00" content-type="application/pdf"/></DUC><DUC_PDF><File uri="dbgapssws.cgi?blob_id=41130&amp;file=get&amp;page=file" filename="dbGaP 9204 Wu NCI CTEP DUCA 3 9 21.pdf" md5="5c0a934c14b8c952212eb379b910fb85" size="435960" modDate="2021-03-09T15:01:12-05:00" content-type="application/pdf"/></DUC_PDF><GSR_Access gsr_mode="contr_access" gsr_mode_label="Controlled-access (GSR are sensitive according to the Institutional Certification)"/><ConsentGroup uid="4432" CGType="cg_class_HMB" title="Health/Medical/Biomedical (COL)" name="HMB-COL" dac_uid="59" dac_name="NCI DAC" irb-approval-required="No" collaboration-required="Yes"><Use-Restriction>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Requestor must provide a letter of collaboration with the primary study investigator(s).

The letter of collaboration for this study is the CTEP Notification e-mail described in the &#8220;CTEP CRADA Collaborator Review Process,&#8221; which can found at the end of the dataset's Data Use Certification Agreement (see dbGaP study page). The &#8220;CTEP CRADA Collaborator Review Process&#8221; describes the process and timeline for DAC review, and also includes a template for the CTEP notification e-mail. Requestor must first send a CTEP Notification e-mail to NCICTEPDAR@mail.nih.gov, and then upload a copy of this e-mail as part of their data access request for this dataset. Please review the &#8220;CTEP CRADA Collaborator Review Process&#8221; carefully to understand the additional terms for this dataset, and contact NCICTEPDAR@mail.nih.gov or NCIDAC@mail.nih.gov regarding any questions.</Use-Restriction></ConsentGroup><AdditionalEmails><Email>NCICTEPDAR@mail.nih.gov</Email></AdditionalEmails></Policy><SRA/><Documents/><Status uid="1" name="released" title="Released"/></Study></dbgapss>